Treatment using the class I-specific HDAC inhibitor MS-275 or the pan HDAC inhibtor TSA induced PDLIM2 re-expression in human lung cancer cell lines or epithelial cell line transformed by K-RasQ61H oncogenic mutant (Fig. 2n, Supplementary Fig. 2h, i). Here, PDLIM2 is linked to lung carcinoma.